Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT TB: Weekly Rifapentine/Isoniazid vs Daily Isoniazid for Latent Tuberculosis Infection
NCT00023452Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Jun 2001
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of rifapentine in Tuberculosis (TB) (2 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Cumulative Rate of Culture-Confirmed TB Disease in Participants >=18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants <18 Years of Age at 33 months. Started Jun 2001; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00023452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023452.